edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Cantargia
Edison Investment Research has terminated coverage on Cantargia (CANTA). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Cantargia — 8 videos in collection
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on NSCLC and pancreatic cancer. The most advanced trial is in Phase II.
• Please explain the link between cancer, autoimmune and inflammatory disorders.
• How does CAN04 differ from other treatments?
• What results have you seen in recent CAN04 tests?
• What is your R&D strategy for nadunolimab?
• What data should we expect and when?
• How does your other asset, CAN10, which has an autoimmune focus, fit in your plans?
Get access to the very latest content matched to your personal investment style.